SCHEMBL20186906

SCHEMBL20186906

Cc1cccc([N+](=O)[O-])c1Nc1ncnc2c(C(=O)O)csc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
KMT2A Q03164 3/20 0.45
KCNMA1 Q12791 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TSHR P16473 1/20 0.41
EGFR P00533 2/20 0.39
NPC1 O15118 2/20 0.39
ALDH1A1 P00352 2/20 0.39
RAB9A P51151 2/20 0.39
GAA P10253 1/20 0.39
MEN1 O00255 2/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ASPH Q12797 1/20 0.38
KDM8 Q8N371 1/20 0.38
LMNA P02545 2/20 0.37
STAT3 P40763 1/20 0.36
LCK P06239 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20186931 0.86 KMT2A (0.47) MAPTKMT2AKCNMA1L3MBTL1TSHR
SCHEMBL20200108 0.84 KDM4E (0.50) MAPTKMT2ATDP1L3MBTL1EGFR
SCHEMBL20186936 0.83 KMT2A (0.45) MAPTKMT2AKCNMA1L3MBTL1TSHR
SCHEMBL20186938 0.82 KMT2A (0.44) MAPTKMT2AKCNMA1L3MBTL1TSHR
SCHEMBL20186943 0.82 RAF1 (0.45) MAPTKMT2AKCNMA1NPC1ALDH1A1
SCHEMBL9930746 0.75 DHODH (0.49) KMT2ATDP1TSHREGFRALDH1A1
SCHEMBL9930841 0.71 YTHDC1 (0.35) MAPTTSHRALDH1A1GAAPOLB
SCHEMBL13652883 0.71 KCNMA1 (0.57) MAPTKMT2AKCNMA1TDP1L3MBTL1
SCHEMBL9930406 0.71 MEN1 (0.44) KMT2AL3MBTL1NPC1RAB9AMEN1
SCHEMBL9930023 0.68 RAF1 (0.34) MAPTNPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS CDK2, CDK2AP2, CDK2AP1 MAPT 2542/4885KMT2A 1357/4885KCNMA1 2556/4885
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors CDK2, CDK2AP2, CDK2AP1 MAPT 2542/4885KMT2A 1357/4885KCNMA1 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.